Academic Journal
Ribociclib leverages phosphodiesterase 4 inhibition in the treatment of neutrophilic inflammation and acute respiratory distress syndrome
| Title: | Ribociclib leverages phosphodiesterase 4 inhibition in the treatment of neutrophilic inflammation and acute respiratory distress syndrome |
|---|---|
| Authors: | Po-Jen Chen, Shun-Hua Chen, Yu-Li Chen, Yi-Hsuan Wang, Cheng-Yu Lin, Chun-Hong Chen, Yung-Fong Tsai, Tsong-Long Hwang |
| Source: | Journal of Advanced Research, Vol 62, Iss , Pp 229-243 (2024) |
| Publisher Information: | Elsevier, 2024. |
| Publication Year: | 2024 |
| Collection: | LCC:Medicine (General) LCC:Science (General) |
| Subject Terms: | Acute respiratory distress syndrome, Ribociclib, Neutrophilic inflammation, Phosphodiesterase 4, Medicine (General), R5-920, Science (General), Q1-390 |
| More Details: | Introduction: Overwhelming neutrophil activation and oxidative stress significantly contribute to acute respiratory distress syndrome (ARDS) pathogenesis. However, the potential of repurposing ribociclib, a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor used clinically in cancer treatment, for treating neutrophilic ARDS remains uncertain. This study illustrated the ability and underlying mechanism of ribociclib for treating ARDS and neutrophilic inflammation. Methods: Primary human neutrophils were used to determine the therapeutic effects of ribociclib on respiratory bursts, chemotactic responses, and inflammatory signaling. In vitro and silico analyses were performed to determine the underlying molecular mechanisms. The potential of ribociclib repurposing was evaluated using an in vivo ARDS model in lipopolysaccharide (LPS)-primed mice. Results: We found that treatment using ribociclib markedly limited overabundant oxidative stress (reactive oxygen species [ROS]) production and chemotactic responses (integrin levels and adhesion) in activated human neutrophils. Ribociclib was also shown to act as a selective inhibitor of phosphodiesterase 4 (PDE4), thereby promoting the cyclic adenosine monophosphate (cAMP)-protein kinase A (PKA) pathway, leading to the inhibition of extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) phosphorylation, and calcium influx. Notably, prophylactic administration and post-treatment with ribociclib ameliorated neutrophil infiltration, lung inflammation, accumulation of oxidative stress, pulmonary destruction, and mortality in mice with LPS-induced ARDS. Conclusion: We demonstrated for the first time that ribociclib serves as a novel PDE4 inhibitor for treating neutrophilic inflammation and ARDS. The repurposing ribociclib and targeting neutrophilic PDE4 offer a potential off-label alternative for treating lung lesions and other inflammatory conditions. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 2090-1232 |
| Relation: | http://www.sciencedirect.com/science/article/pii/S209012322400119X; https://doaj.org/toc/2090-1232 |
| DOI: | 10.1016/j.jare.2024.03.019 |
| Access URL: | https://doaj.org/article/253e57a5843748d2a16b88013cc43780 |
| Accession Number: | edsdoj.253e57a5843748d2a16b88013cc43780 |
| Database: | Directory of Open Access Journals |
| ISSN: | 20901232 |
|---|---|
| DOI: | 10.1016/j.jare.2024.03.019 |
| Published in: | Journal of Advanced Research |
| Language: | English |